Automated astatination of biomolecules--a stepping stone towards multicenter clinical trials.
Journal article, 2015

To facilitate multicentre clinical studies on targeted alpha therapy, it is necessary to develop an automated, on-site procedure for conjugating rare, short-lived, alpha-emitting radionuclides to biomolecules. Astatine-211 is one of the few alpha-emitting nuclides with appropriate chemical and physical properties for use in targeted therapies for cancer. Due to the very short range of the emitted α-particles, this therapy is particularly suited to treating occult, disseminated cancers. Astatine is not intrinsically tumour-specific; therefore, it requires an appropriate tumour-specific targeting vector, which can guide the radiation to the cancer cells. Consequently, an appropriate method is required for coupling the nuclide to the vector. To increase the availability of astatine-211 radiopharmaceuticals for targeted alpha therapy, their production should be automated. Here, we present a method that combines dry distillation of astatine-211 and a synthesis module for producing radiopharmaceuticals into a process platform. This platform will standardize production of astatinated radiopharmaceuticals, and hence, it will facilitate large clinical studies focused on this promising, but chemically challenging, alpha-emitting radionuclide. In this work, we describe the process platform, and we demonstrate the production of both astaine-211, for preclinical use, and astatine-211 labelled antibodies.

Author

Emma Aneheim

University of Gothenburg

Per Albertsson

University of Gothenburg

Tom Bäck

University of Gothenburg

Holger Jensen

Stig Palm

University of Gothenburg

Sture Lindegren

University of Gothenburg

Scientific Reports

2045-2322 (ISSN)

Vol. 5 article no. 12025-

Subject Categories

Radiology, Nuclear Medicine and Medical Imaging

DOI

10.1038/srep12025

PubMed

26169786

More information

Created

10/10/2017